Analytical method demonstrates high precision and recovery in bulk and injectable forms, indicating reliability for quality control.
An Easy, sensitive, specific, and precise RP-UPLC method for the pharmaceutical dose estimation of Bevacizumab in injectable dosage form. Chromatogram was run through ACQUITY UPLC HSS C18 Column, 130A, 1.7 um, 2.1 mm X 100 mm. Mobile phase containing 0.1% OPA: Acetonitrile taken in the ratio 60:40 was pumped through column at a flow rate of 0.3ml/min. Temperature was maintained at 30.7°C. Optimized wavelength selected was 215.0nm. Retention time of Bevacizumab was found to be 0.945 min. %RSD of the Bevacizumab were and found to be 0.8. %RSD of Method precision of Bevacizumab was found to be 0.2 %Recovery was obtained as 99.75% for Bevacizumab. LOD, LOQ values obtained from regression equation of Bevacizumab were 0.05, 0.16. Regression equation of Bevacizumab is y = 11549x + 1531.9. Retention times were decreased and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.
No takes yet. Share an insight, caveat, or question.
Bhushan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: